<DOC>
	<DOC>NCT02149771</DOC>
	<brief_summary>The purpose of this study is to determine whether TACE combined endovascular stent implantation confers a survival benefit over TACE alone.</brief_summary>
	<brief_title>Combination Treatment for Advanced Liver Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>(1) Hepatocellular carcinoma(HCC) diagnosis confirmed by needle biopsy or by two coincidental imaging techniques associated with increased αfetoprotein according to the American Association for the Study of Liver Diseases (AASLD) guidelines and contrastenhancing tumour thrombus within the main portal vein and one of the firstorder branch on CT or MRI; (2) ChildPugh classification grade A or B； （3）Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less. advanced liver disease (bilirubin levels &gt;3 mg/dL, ASTor ALT &gt;5 × upper limit of normal)； Tumor invade the Inferior Vena Cava, extrahepatic spread; contraindications for doxorubicin or oxaliplatin chemotherapy; any contraindication to an arterial procedure such as impaired clotting tests (platelet count below 50 × 109/L or prothrombin activity below 50 %); renal failure,cardiac ejection fraction &lt;50 %) or endstage disease； patients who were not capable of cooperation during the procedure.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>portal vein tumor thrombosis</keyword>
	<keyword>stents</keyword>
	<keyword>chemoembolization</keyword>
</DOC>